Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Sermorelin

GHRH (1-29), GRF 1-29 NH2, Sermorelin acetate

Quick Stats
Studies 223
Trials 41
Score 2
2016 pubmed 31 citations

Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS.

Knoop. Andre A; Thomas. Andreas A; Fichant. Eric E; Delahaut. Philippe P; Schänzer. Wilhelm W; Thevis. Mario M

Key Findings

  • A new immuno‑affinity LC‑HRMS/MS method can detect sermorelin and related GHRHs in plasma at <50 pg/mL
  • Sermorelin (Geref) remains detectable for at least 4 hours after injection
  • A human‑specific metabolite (GHRH3‑29) was identified, while expected metabolites were not seen in rat samples

Practical Outcomes

  • If you’re using sermorelin, know it can be detected in blood for several hours, which may affect drug‑testing outcomes. The study doesn’t give dosing advice, but highlights that current detection methods are sensitive enough to catch use, so timing and concealment strategies are limited.

Summary

Researchers created a sensitive blood test that can spot sermorelin and similar growth‑hormone‑releasing peptides, even at very low levels. They found the drug stays intact in the blood for at least four hours and that a specific breakdown product shows up in humans but not in rats. This method could be used in anti‑doping labs to catch people using these peptides.

Abstract

The use of growth hormone-releasing hormones (GHRHs) is prohibited in sports according to the regulations of the World Anti-Doping Agency (WADA). The aim of the present study was to develop a method for the simultaneous detection of four different GHRHs and respective metabolites from human plasma by means of immunoaffinity purification and subsequent nano-ultrahigh performance liquid chromatography-high resolution/high accuracy (tandem) mass spectrometry. The target analytes included Geref (Sermorelin), CJC-1293, CJC-1295, and Egrifta (Tesamorelin) as well as two metabolites of Geref and CJC-1293, which were captured from plasma samples using a polyclonal GHRH antibody in concert with protein A/G monolithic MSIA&#x2122; D.A.R.T.'S&#xae; (Disposable Automation Research Tips) prior to separation and detection. The method was fully validated and found to be fit for purpose considering the parameters specificity, linearity, recovery (19-37%), lower limit of detection (&lt;50 pg/mL), imprecision (&lt;20%), and ion suppression/enhancement effects. The analytes' stability and metabolism were elucidated using in vitro and in vivo approaches. EDTA blood samples were collected from rats 2, 4, and 8 h after intravenous administration of GHRH (one compound per test animal). All intact substances were detected for at least 4 h but no anticipated metabolite was confirmed in laboratory rodents' samples; conversely, a Geref metabolite (GHRH3-29) was found in a human plasma sample collected after subcutaneous injection of the drug to a healthy male volunteer. The obtained results demonstrate that GHRHs are successfully detected in plasma using an immunoaffinity-mass spectrometry-based method, which can be applied to sports drug testing samples. Further studies are however required and warranted to account for potential species-related differences in metabolism and elimination of the target analytes.

Study Information

Provider

pubmed

Year

2016

Date

2016-02-15T00:00:00.000Z

DOI

10.1007/s00216-016-9377-3

Citations

31

References

30